SEC Form 4 · accession 0001628280-26-044346
MADRIGAL PHARMACEUTICALS, INC. · MDGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rebecca Taub
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 4:23 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001157601
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 17, 2026 | A | 454 | $0.00 | A | 452,667 | D | |
| Common StockF2 | holding | — | — | — | 655,540 | I | By SQN LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $499.86 | Jun 17, 2026 | A | 766 | A | — | Jun 17, 2036 | Common Stock | 766 | 766 | D |
Explanation of responses
- F1Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
- F2The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F3The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.